Introduction

Parkinson’s disease (PD) is the second most common neurological illness among those over the age of 65 [1]. The selective loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) and DA levels in the corpus striatum of the nigrostriatal DA pathway in the brain are linked to PD. Because of the loss of DA, the basal ganglia circuitries become dysregulated, resulting in motor symptoms including bradykinesia, resting tremor, stiffness, and postural instability, as well as non-motor symptoms like sleep difficulties, depression, and cognitive deficiencies [2]. The role of oxidative stress in the etiopathology of this illness is widely acknowledged. Increased quantities of oxidized lipids, proteins, and DNA are seen in the SN of PD patients. Furthermore, in PD brains, levels of reduced glutathione (GSH), the most common thiol-reducing agent, are much lower, indicating oxidative stress and nigral degeneration [3]. Chronic neuroinflammation is another key source of ROS in PD patients. Proinflammatory cytokines build up in PD patients’ cerebrospinal fluid and are elevated in postmortem brain samples and experimental models of the illness [4].

Despite advances in our understanding of the pathophysiology of PD, recent research have shown that the Nrf2 (NF-E2-related factor 2)/antioxidant responsive element (ARE) signaling cascade is the most potential target for therapeutic treatment [5].

It is a Cap’n’Collar transcription factor expressed in most brain cell types, including DAergic neurons, astroglia, and microglia, where it contributes to redox homeostasis by regulating the expression of antioxidant genes [6,7,8]. Several experimental evidence clearly imply that Nrf2 has a role in the neuroprotection of DAergic neurons. In fact, in parkinsonian SN DAergic neurons, Nrf2 translocates to the nucleus, but in normal age-matched controls, it stays cytosolic. This is seen as an attempt to keep ROS production under check [9, 10].

Because oxidative stress play a key role in the majority of instances of Parkinson’s disease, it is critical to comprehend the significance of diet in neuroprotection. Some foods have shown promise in lowering the incidence of Parkinson’s disease in recent epidemiological research [11]. The health advantages linked with the consumption of phytochemicals found in fruits and vegetables result in less functional loss as people age, which may help to halt the onset of Parkinson’s disease [12]. High consumption of fruits, vegetables, and fish was found to be inversely related to the risk of Parkinson’s disease in epidemiological research [13, 14].

Açai seeds have recently piqued the interest of scientists. Açai berry is a berry that has a wide range of nutritional characteristics as well as some medicinal potential. This sour and pleasant-tasting fruit comes from the Euterpe Oleracea palm, which is only found in the Amazon. The Açai fruit, which is considered a high-energy meal, has been used by Amazonian Indians for millennia as a food source and natural cure for a variety of ailments [15,16,17,18,19,20,21,22,23].

Because of the Açai berry’s high bioactivate nutritional and phytochemical content, its pulp has been widely studied. The composition of Açai berry pulp revealed that it includes a variety of physiologically active phytochemicals as well as large levels of mono- and polyunsaturated fatty acids do not present in most fruits and other berries. Açai pulp contains phytochemicals such as anthocyanins, proanthocyanidins, and other flavonoids. Furthermore, phytochemical tests found that the Açai berry contains various forms of anthocyanins, including cyanidin, delphinidin, malvidin, pelargonidin, and peonidin, as well as a high concentration of luteolin, quercetin, dihydrokaempferol, and chrysoerial, among other polyphenolics. Carotenoids were found in Açai berry pulp in five different forms: carotene, lycopene, astaxanthin, lutein, and zeaxanthin [24].

Açai berry extract and its bioactive content have a wide range of pharmacological effects, including anti-inflammatory, antioxidant, anticarcinogenic, and neuroprotective characteristics, according to a large body of research [25]. However, there is currently a scarcity of scientific data to support the favorable neuroprotective effects. For this reason, we used a consolidated murine model of PD, to investigate the potential beneficial effects of Açai supplementation and the molecular way by which its acts.

Material and Methods

Animals

C57/BL6 mice (male 25–30 g, 8 weeks age old; Envigo, Italy) were accommodated in a controlled environment and equipped with standard rodent chow and water. The University of Messina Review Board for animal care (OPBA) approved the study. All animal experiments agree with the new Italian regulations (D.Lgs 2014/26), EU regulations (EU Directive 2010/63), and the ARRIVE guidelines.

Parkinson Disease Induction

Mice received four intraperitoneal injections of 20 mg/kg of MPTP (Sigma, St. Louis, MO) in saline at 2-h intervals in 1 day, the entire dose per mouse being 80 mg/kg [26].

Experimental Groups

Mice were indiscriminately distributed to the following groups:

  • Sham = vehicle solution (saline) was administered intraperitoneally during the 1st day, as for MPTP.

  • Sham + Açai = same as the Sham group, but Açai berry (500 mg/kg) (dissolved in saline) was orally administered starting 24 h after the first vehicle solution injection and continuing through 7 additional days after the last injection of saline (data not shown).

  • MPTP = MPTP was administered as described above plus administration of saline.

  • MPTP + Açai = but Açai berry (500 mg/kg) (dissolved in saline) was orally administered starting 24 h after the first vehicle solution injection and continuing through 7 additional days after the last injection of saline.

At the conclusion of the experiment, mice were sacrificed under anesthesia and the brain removed and fixed in 10% neutral-buffered formalin or stored at − 70 °C for biochemical and molecular analyses.

Behavioral Testing

Behavioral assessments on each mouse were made 7 days after MPTP injection. Behavioral data analysis was performed by observers who were unaware of the experimental groups.

  • Pole test (PT): The PT was performed as previously described [27]. Briefly, mice are placed with their head upwards right below the top. Two parameters were assessed: time until the animal turned by 180°, and total time until the animal descended to the floor [27].

  • Rotarod test (RT): Motor activity was assessed with rotary rod apparatus using a protocol previously described [28, 29]. In brief, after the training sessions, animal was placed back on the drum immediately after falling up to five times in one session.

  • Balance beam walking (BBW): The mice were placed to a batten and enticed to cross a timber balancing beam with food [30]. If the mouse slid off, the test was halted and restarted. The time it took a mouse to cross the balancing beam successfully was recorded.

  • Grid walking (GW): The grid walking test was used to assess the sensorimotor coordination of mice’s hindlimbs. When a paw totally failed to hold a rung, an independent experimenter tallied the number of hindlimb slides. The average of the foot slips was used for analysis after each experiment was done three times [30].

  • Cylinder test (CiT): When mice are maintained in a new transparent cylinder, they investigate by moving around and elevating their bodies to contact the cylinder walls with their forelimbs; this is known as rearing. Before another rearing, we only counted when the mouse elevated both forelimbs above shoulder level and removed both forelimbs from the cylinder [31].

  • Catalepsy test (CaT): Catalepsy, demarcated as a reduced capability to start movement and a failure to correct posture, was measured as previously described [32, 33]. In particular, after the training the length of time the mice maintained this position was recorded.

  • Elevated plus-maze test (EPM): EPM was performed as previously described [34, 35]. The EPM test was performed to evaluated the anxiety state as described previously [35, 36]. Briefly, after the training session, the number of entries into each arm and the number of crossings were recorded.

  • Open field test (OFT): Locomotor activity and anxiety-like behavior were monitored by the OFT. After a training session, each mouse was gently placed in the center of the box, and activity was scored as a line crossing when a mouse removed all four paws from one square and entered another [37, 38].

  • Tail suspension test (TST): The tail suspension test is a desperation-based test that measures how long animals remain immobile after being subjected to inexorable conditions. Mice were only considered immobile when they were fully still [39].

  • Forced swimming test (FST): The duration of floating (i.e., the time during which the mice made just the modest movements required to keep their heads above water) was scored after each mouse was gently placed in the cylinder for 6 min as previously described [40, 41].

  • Von Frey test (VFT): When the paw was inadvertently contacted with von Frey filament, each mouse was watched for paw withdrawal reflex as previously described [42].

  • Tail-flick test (TFT): When each mouse’s tail was dipped in a water bath kept at a constant temperature (53 °C), a tail flick response was observed. The experiment was videotaped, and the animal’s reaction time (tail flick) was recorded [42].

Histology

Brain sections were stained with hematoxylin/eosin (H/E) and studied under light microscopy connected to an imaging system Leica DM6 microscope (Leica Microsystems SpA, Milan, Italy) with Leica LAS X Navigator software (Leica Microsystems SpA). [43]. Histological assessment was made by a blinded observer, and slides were scored for severity of pathological profiles after H/E staining using a semiquantitative 5-point rating scale, as previously described by [43,44,45,46,47].

Western Blot Analysis of IκBα, GFAP, Iba-1, Nrf2, HO-1, NF-κB p65, Bax, Bcl-2, β-Actin, and Lamin A/C

Western blot analysis was performed as previously described [48,49,50,51,52,53]. The following primary antibodies were used: IκBα (1–500 Santa Cruz Biotechnology, Heidelberg, Germany #sc1643), glial fibrillary acidic protein (GFAP) (1–500 Santa Cruz Biotechnology, Heidelberg, Germany #sc33673), Iba-1 (1–500 Santa Cruz Biotechnology, Heidelberg, Germany #sc32725), Nrf2 (1–500, Santa Cruz Biotechnology, Heidelberg, Germany, #sc-365949), anti-heme oxygenase 1 (HO-1) (1–500, Santa Cruz Biotechnology, Heidelberg, Germany, #sc-136960), nuclear factor-kappaB (NF-κB) p65 (1–500, Santa Cruz Biotechnology, #sc8414), Bax (1–500 Santa Cruz Biotechnology, Heidelberg, Germany #sc20067), and Bcl-2 anti-Bcl-2 (1–500, Santa Cruz Biotechnology, Heidelberg, Germany, #sc7382) at 4 °C overnight in 1 × PBS, 5% (w/v), non-fat dried milk, and 0.1% Tween-20. For the cytosolic fraction, Western blots were also explored with antibody against β-actin protein (1:500, Santa Cruz Biotechnology, Dallas, TX, USA). The same methods were used for nuclear fraction with lamin A/C (1:500, Sigma-Aldrich Corp., Milan, Italy) [45, 54]. Signals were examined with an enhanced chemiluminescence (ECL) detection system reagent, according to the manufacturer’s instructions (Thermo, Monza, Italy). The relative expression of the protein bands was quantified by densitometry with BIORAD ChemiDocTM XRS+ software [55,56,57,58,59].

Immunohistochemical Localization of TH, Dopamine Transporter (DAT), α-Synuclein, GFAP, and Iba-1

The immunohistochemical techniques used have been previously described [52, 58, 60]. Slices were incubated overnight with one of the following primary antibodies (specific for each whether polyclonal or monoclonal): anti-TH (Millipore, 1:500 in PBS, v/v), anti-DAT (Santa Cruz Biotechnology, 1:300 in PBS, v/v), anti-α-syn (Santa Cruz Biotechnology, 1:50 in PBS, v/v), anti-Iba-1 (Santa Cruz Biotechnology, 1:300 in PBS, v/v), and anti-GFAP (Santa Cruz Biotechnology; 1:200 in PBS, v/v). Immunohistochemical images were collected using Leica DM6 (Milan, Italy) associated with an Imaging system (LasX Navigator, Milan, Italy). The digital images were opened in ImageJ, followed by IHC profiler plug-in. All immunohistochemical analyses were carried out by two observers blinded to the treatment [29, 54, 61,62,63].

Immunofluorescence Co-localization of TH/α-syn

Sections were incubated with the following primary antibodies: polyclonal anti-TH (1:250; Merck-Millipore) and monoclonal anti-α-syn (1:50; Santa Cruz Biotechnology) as previously described [51]. Sections were washed with PBS and were incubated with secondary antibody TEXAS RED-conjugated anti-rabbit Alexa Fluor-594 antibody (1:1000 in PBS, v/v Molecular Probes, UK) and with FITC-conjugated anti-mouse Alexa Fluor-488 antibody (1:2000 v/v Molecular Probes, UK) for 1 h at 37 °C. Sections were rinsed and stained for nuclear signal with 4′,6′-diamidino-2-phenylindole (DAPI; Hoechst, Frankfurt; Germany) 2 μg/ml in PBS. Sections were observed and photographed at × 100 magnification using a Leica DM2000 microscope.

Tunel Staining

TUNEL staining protocol was according to a Roche protocol as previously described [45, 64,65,66]. Tunel staining was also incubated with anti-TH (1:250; Merck-Millipore) and FITC-conjugated anti-mouse Alexa Fluor-488 antibody (1:2000 v/v Molecular Probes, UK) for 1 h at 37 °C and then observed with Leica DM6 (Milan, Italy) associated with an Imaging system (LasX Navigator, Milan, Italy).

Cytokine Measurement

TNF-α, IL-1β, and IL-6 levels were measured as previously described using a commercially available enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN, USA) kits according to the manufacturer’s instructions [67].

Myeloperoxidase and Malondialdehyde Measurement

MPO activity, an index of neutrophilic granulocyte infiltration, was evaluated as previously described and expressed as U/mg of tissue [52]. Lipid peroxidation were assessed with malonaldehyde as previously described and expressed as nmol/mg of proteins [68].

Oxidative Stress and Antioxidant Defense

SOD, CAT, GPX, and GPx in the brain tissues were investigated as previously described [69, 70]. ROS content was measured using commercial kits according to manufacturer guidelines [71].

Materials

Unless otherwise stated, all compounds were obtained from Sigma-Aldrich.

Statistical Evaluation

In this study, the data are expressed as the average ± SEM and represent at least 3 experiments carried out in different days. For in vivo studies, N represents the number of animals used. The number of animals used for in vivo studies was carried out by G*Power 3.1 software (Die Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany). Data were analyzed by an experienced histopathologist, and all the studies were performed without knowledge of the treatments. The results were analyzed by one-way ANOVA followed by a Bonferroni post hoc test for multiple comparisons. A p value less than 0.05 was considered significant.

Results

Açai Supplementation Reduces Both Motor and Non-motor Deficits

The most known symptoms that unfortunately afflict people with Parkinson’s are represented by motor alterations [72]. For this reason, we investigated by different behavioral test such as pole test (Fig. 1A and B), rotarod test (Fig. 1C and D), balance beam walking (Fig. 1E), grid walking (Fig. 1F), cylinder test (Fig. 1G), and catalepsy test (Fig. 1H) motor alteration MPTP-induced. Animals subjected to MPTP induction showed significantly motor alteration such as an increasing in the time spent on pole to as well as an increase in time spent on the rotarod apparatus and an increase in the time spent to reach the goal or to explore the space. After the daily oral administration with Açai we registered a significantly decrease in this alteration and an almost return to the physiological conditions of the animal. PD can also be considered a neuropsychiatric disorder [73]. Several neuropsychiatric symptoms are in fact related to emotional and cognitive problems [74]. Also, in this case, we investigated behavioral alteration with a series of tests useful to investigated anxiety, depression and pain. In particular, we used elevated plus maze test (Fig. 2A and B), open field test (Fig. 2C and D), tail suspension test (Fig. 2E), forced-swimming test (Fig. 2F), Von Frey test (Fig. 2G), and tail-flick test (Fig. 2H). As supposed, we found a significantly mood alterations after MPTP induction with an increase in anxiety and depression state and a reduction in nociceptive stimuli. Açai administration was able to reduce behavioral alterations restoring also nociceptive sensitivity.

Fig. 1
figure 1

Açai supplementation reduces motor deficits. Total time (A) and time to turn (B) on pole test; time (C) and number of falls (D) on rotarod test; balance beam walking (E); number of foot on grid walking (F); cylinder test (G) and catalepsy test (H). See manuscript for further details. Values are means ± SEM of 6 mice for all group. ***p < 0.001 vs. sham; ###p < 0.001 vs. MPTP

Full size image
Fig. 2
figure 2

Açai supplementation reduces non motor deficits. Time in open arm (A) and number of crossing (B) during elevated plus maze test; number of line crossing (C) and number of rearing (D); tail suspension test (E); forced swimming test (F); latency during von Frey test (G) and latency during tail flick test (H). See manuscript for further details. Values are means ± SEM of 6 mice for all group. ***p < 0.001 vs. sham; ###p < 0.001 vs. MPTP

Full size image

Açai Berry Limits Histological Alteration MPTP-Induced

At the end of the experiment, brain samples were collected and stained for hematoxylin/eosin. Section of brain from the control group showing normal parenchymal and neurons (Fig. 3A and see relative histological score in Fig. 3D). Brain slices from MPTP group significantly showing alteration in brain tissue and a reduction in neuronal number (Fig. 3B and see relative histological score in Fig. 3D). Açai daily administration showing a marked reduction of degeneration and an increased number of SNpc neurons (Fig. 3C and see relative histological injury score in Fig. 3D). Additionally, we evaluated the decrease in body weight MPTP-induced. As shown in Fig. 3E, we observed a significantly reduction in body weight loss after 7 days of Açai administration.

Fig. 3
figure 3

Açai berry limits histological alteration MPTP-induced. Brain section stained with H/E of Sham (A), MPTP (B), and MPTP + Açai (C); histological score (D); percentual in body weight changes (E). Scale bar 100 μm represents 20 × magnification. See manuscript for further details. Values are means ± SEM of 6 mice for all group. ***p < 0.001 vs. sham; ###p < 0.001 vs. MPTP

Full size image

Açai Supplementation Restores TH and DAT Loss MPTP-Induced

We assessed the degree of midbrain neuronal cell degeneration in terms of loss of TH+ in the substantia nigra and modification of DAT levels in the striatum because its well know that TH activity and DA levels are lowered in PD brain [51]. When MPTP-injected mice (Fig. 4B and F, see respectively densitometric analysis in Fig. 4D and H) were compared to sham mice (Fig. 4A and E, see respectively densitometric analysis in Fig. 4D and H), immunohistochemical examination revealed a clear decrease in terms of TH and DAT expression. Açai administration at the dose of 500 mg/kg for 7 days considerably restored TH and DAT levels (Fig. 4C and G, see respectively densitometric analysis in Fig. 4D and H).

Fig. 4
figure 4

Açai supplementation restores TH and DAT loss MPTP-induced. Immunohistochemical localization of TH and DAT in brain section of Sham (A and E), MPTP (B and F) and MPTP + Açai (C and G); quantification of positive pixel of TH+ (D) and DAT+ (H). See manuscript for further details. Scale bar 100 μm represents 20 × magnification. Scale bar 250 μm represents 10 × magnification. Values are means ± SEM of 6 mice for all group. ***p < 0.001 vs. sham; ###p < 0.001 vs. MPTP

Full size image

Açai Berry Reduce α-Syn Aggregation

The Lewy body contains a lot of misfolded α-syn [75]. In comparison to sham animals (Fig. 5A and densitometric analysis in Fig. 5D), MPTP injection resulted in a large increase in α-syn accumulation (Fig. 5B and densitometric analysis in Fig. 5D). On the other hand, Açai administration was able to reduce the accumulation of misfolded α-syn (Fig. 5C and densitometric analysis in Fig. 5D). To better appreciate misfolded α-syn aggregation in dopaminergic neurons, we made immunofluorescence co-localization. We did not find any positive co-localization in sham animals (Fig. 5E and densitometric analysis in Fig. 5H), whereas MPTP injection resulted in a significantly α-syn accumulation in dopaminergic neurons (Fig. 5F and densitometric analysis in Fig. 5H). Açai administration significantly reduced the accumulation α-syn in dopaminergic neurons (Fig. 5G and densitometric analysis in Fig. 5H).

Fig. 5
figure 5

Açai berry reduce α-syn aggregation. Immunohistochemical localization of α-syn in brain section of Sham (A), MPTP (B), and MPTP + Açai (C); quantification of positive pixel of α-syn+ (D). Immunofluorescence co-localization on TH/α-syn in brain section of Sham (E), MPTP (F), and MPTP + Açai (G); number of positive cells/field (H). Yellow arrow indicates the expression of both markers. See manuscript for further details. Scale bar 75 μm represents 40 × magnification. Scale bar 25 μm represents 100 × magnification. Values are means ± SEM of 6 mice for all group. ***p < 0.001 vs. sham; ###p < 0.001 vs. MPTP

Full size image

Açai Supplementation Counteracts Astrogliosis and Microgliosis

While glia and astrocytes are required for maintaining homeostasis in the healthy brain, their malfunction contributes to neurodegeneration in a variety of illnesses, including PD. By western blots and immunohistochemical staining we investigates the expression of GFAP and Iba-1, well know markers of astrocytosyis and microgliosys. We notice that after MPTP induction, there were a significant increase in both GFAP (see Fig. 6A and relative densitometric analysis in Fig. 6A1 for western blot and Fig. 6D and relative densitometric analysis in 6F for immunohistochemical) and Iba-1 (see Fig. 6B and relative densitometric analysis in Fig. 6B1 for western blot and Fig. 6H and relative densitometric analysis in Fig. 6J for immunohistochemical) expressions compared to sham animals (see Fig. 6A and relative densitometric analysis in Fig. 6A1 for western blot and Fig. 6G and relative densitometric analysis in Fig. 6F for immunohistochemical of GFAP; Fig. 6B and relative densitometric analysis in Fig. 6B1 for western blot and Fig. 6G and relative densitometric analysis in Fig. 6J for immunohistochemical of Iba-1). Daily administration of Açai at the dose of 500 mg/kg significantly reduce both expressions (see Fig. 6A and relative densitometric analysis in Fig. 6A1 for western blot and Fig. 6E and relative densitometric analysis in Fig. 6F for immunohistochemical of GFAP; Fig. 6B and relative densitometric analysis in Fig. 6B1 for western blot and Fig. 6I and relative densitometric analysis in Fig. 6J for immunohistochemical of Iba-1).

Fig. 6
figure 6

Açai supplementation counteract astrogliosis and microgliosis. Western blots and relative densitometric analysis of GFAP (A and A1) and Iba-1 (B and B1). Immunohistochemical localization of GFAP and Iba-1 in brain section of Sham (C and G), MPTP (D and H), and MPTP + Açai (E and I); quantification of positive pixel of GFAP+ (F) and Iba-1+ (J). See manuscript for further details. Scale bar 25 μm represents 100 × magnification. Values are means ± SEM of 6 mice for all group. ***p < 0.001 vs. sham; ###p < 0.001 vs. MPTP

Full size image

Açai Berry Reduces Proinflammatory Cytokine Release, Neutrophilic Infilitration, and Lipid Peroxidation

MPTP triggers an inflammatory response that aids in the progression of neurodegeneration. The proinflammatory cytokines TNF-α, IL-1β, and IL-6 are produced by astrocytes and glia [76]. By ELISA kit, we investigated brain release of proinflammartory cytokines and we found a significantly increase in TNF-α (Fig. 7A), IL-1β (Fig. 7B), and IL-6 (Fig. 7C) after MPTP induction compared to sham group. As supposed, we found a significantly decrease after Daily administration of Açai. MPO and MDA levels in brain tissue have been found to be elevated in numerous neurodegenerative diseases [77, 78]. In accordance with the bibliography, we found a significantly increase in MPO and MDA levels after MPTP induction (Fig. 7D) compared to control group. On the other hand, Açai considerably decreases both.

Fig. 7
figure 7

Açai berry reduce proinflammatory cytokine release, neutrophilic infilitration, and lipid peroxidation. ELISA quantification for TNF-α (A), IL-1β (B) and IL-6 (C) MPO quantification (D), and lipid peroxidation (E). See manuscript for further details. Values are means ± SEM of 6 mice for all group. ***p < 0.001 vs. sham; ###p < 0.001 vs. MPTP

Full size image

Açai Supplementation Improves Antioxidant Defense

In PD, oxidative stress plays a key role in the cascade that leads to dopamine cell destruction [79]. We investigated the oxidative stress by the analysis of ROS and antioxidant system, and we found that after MPTP induction, there were an increase in ROS production (Fig. 8A) and a decrease in Nrf-2 (Fig. 8B and relative densitometric analysis in Fig. 8B1) pathways as well as in HO-1 (Fig. 8C and relative densitometric analysis in Fig. 8C1), SOD (Fig. 8D), CAT (Fig. 8E), GPx (Fig. 8F), and GSH (Fig. 8G) compared to sham group. Açai administration 500 mg/kg significantly improve physiological antioxidant defense decreasing ROS production.

Fig. 8
figure 8

Açai supplementation improve antioxidant defense. ROS content (A); Western blots and relative densitometric analysis of Nrf-2 (B and B1) and HO-1 (C and C1); SOD (D); CAT(E); GPx (F) and GSH (G). See manuscript for further details. Values are means ± SEM of 6 mice for all group. ***p < 0.001 vs. sham; ###p < 0.001 vs. MPTP

Full size image

Açai Berry Limits Dopaminergic Neuronal Death

By western blot and colocalization TH/TUNEL, we investigated neuronal death. We found that after Açai administration, there were a significant increase in Bcl-2 expression (Fig. 9A and relavive densitometric analysis in Fig. 9A1) as well as a considerably decrease in Bax expression (Fig. 9B and relavive densitometric analysis in Fig. 9B1) compared to MPTP group. To investigate in particular dopaminergic death, we analyzed TUNEL and TH expression and we found that MPTP significantly induce dopaminergic death (Fig. 9D and apoptotic index in Fig. 9F) compared to sham group (Fig. 9C and apoptotic index in Fig. 9F), whereas Açai at the dose of 500 mg/kg considerably reduces TH+ cell death.

Fig. 9
figure 9

Açai Berry limits dopaminergic neuronal death. Western blots and relative densitometric analysis of Bcl-2 (A and A1) and Bax (B and B1); Immunofluorescence co-localization of TH/TUNEL in brain section of Sham (C), MPTP (D) and MPTP + Açai (E); apoptosis index expressed in percentual (F). See manuscript for further details. Values are means ± SEM of 6 mice for all group. ***p < 0.001 vs. sham; ###p < 0.001 vs. MPTP

Full size image

Discussions

PD is the most prevalent neurological movement disorder, with a global frequency of 0.1% and a prevalence of 3% in those over 65. After the loss of > 50% of dopaminergic (DAergic) neurons in the substantia nigra (SN) pars compacta and > 80% drop in DA levels in the striatum, motor symptoms such as bradykinesia, tremor, and stiffness appear. In addition, psychological comorbidities such as depression and anxiety are frequent in people with Parkinson’s disease, and they lead to considerable functional impairment as well as poor motor and social performance. This results in a lower quality of life and a greater strain on caregivers [80, 81]. Mood disorders are frequently misdiagnosed because their symptoms coincide with the cognitive and motor aspects of Parkinson's disease. As a result, early diagnosis and treatment for anxiety and depression are critical in the treatment of PD [82, 83]. The buildup of α-synuclein-rich protein aggregates, known as Lewy bodies, and a rise in the neuroinflammatory indicators of microgliosis and astrogliosis are the well know anatomopathological hallmarks of the illness [3]. Replacement of striatal DA is the focus of current pharmaceutical treatment. Levodopa crosses the blood–brain barrier and enters the presynaptic neurons via the DA transporter (DAT), where it is converted to DA and stored in vesicles. For decades, these medications, alone or in conjunction with pharmaceuticals that affect cholinergic modulation, have been of great help to most PD patients. However, while these methods alleviate motor symptoms, it is unclear if they aid in slowing the disease’s course [84]. Stopping the chain of events that leads to the development of PD is undoubtedly a major problem that necessitates a neuroprotective strategy to maintain the DAergic neurons that are still viable in the newly diagnosed patient alive and functional. To make progress in this area, a greater understanding of PD etiopathology is required, followed by the identification of molecular targets that might support the development of a neuroprotective medication in the clinic. Although there is no single cause of Parkinson’s disease, evidence from sporadic and familial cases, as well as chemical and genetic animal models, clearly shows that oxidative stress plays a key role in the illness’s onset and development. As a result, pharmaceutical intervention, whether or not to alleviate or counteract excessive ROS generation, might become a novel neuroprotective technique [2].

There is now a variety of early research suggesting that some foods may slow the course of Parkinson’s disease. These findings are not surprising, given that nutrients influence mitochondrial energy function and offer important antioxidant capabilities that reduce oxidative phosphorylation's free radical byproducts. Increased oxidative stress from a poor diet may compromise the antioxidant defense system. A well-balanced diet rich in a range of nutrients, such as several servings of vegetables and fruits, moderate doses of omega-3 fatty acids, tea, coffee, and wine, on the other hand, may give neuroprotection [11, 85]. The new food, generally known as “Açai,” is a berry native to South America that belongs to the Euterpe genus of tropical palm plants. Scientists have been studying Euterpe oleracea because of its high antioxidant content when compared to other fruits and berries. Açai pulp composition research also revealed that it includes several physiologically active phytochemicals. Açai berries have been shown to have neuroprotective qualities in a number of studies [24]. Many of these diseases are multifactorial, resulting from a combination of aging, genetic disorders, and exposure to one or more environmental factors, which cause oxidative stress, chronic neuroinflammation, excitotoxicity, mitochondrial dysfunction, and irregular protein accumulation in brain tissues, among other cellular etiologies. Experiments showed that Açai berry extracts provide neuroprotection by exhibiting antioxidant and anti-inflammatory properties, suppressing harmful protein aggregation, and restoring calcium homeostasis and mitochondrial function, among other things. Açai fruit also has antidepressant and anticonvulsant properties, which might be useful to persons with these neurodisorders [86,87,88,89,90,91,92,93]. With this aim in our mind, we used a consolidated murine model of PD to investigates beneficial effects of Açai supplementation in behavioural disorders as well as against astrogliosis and microgliosis, oxidative stress and apoptosis.

In our study using different behavioral tests, we found that Açai supplementation was in grade to reduces both motor and non motor deficits limiting axiety and depression state as well as tremor, bradikynesia and stiffness. Additionally, we found that that Açai berry supplementation at the dose of 500 mg/kg administred daily limits histological alteration in the substantia nigra MPTP-induced restoring TH and DAT expression as well as was able to reduce α-syn aggregation.

In accordance with the bibliography, we found that Açai berry supplementation was able to counteract astrogliosis and microgliosis as well as proinflammatory cytokine release, neutrophilic infilitration and lipid peroxidation. These beneficial effects are probably due to effects that Açai berry showing on physiological anti oxidant defence. We found that Açai Berry supplementation at the dose of 500 mg/kg administred daily significantly improve Nrf-2 expression as well as HO-1, SOD, CAT, GPx, and GSH reducing oxidative stress general state.

The improvement of anti oxidant defence was also reflected in the reduction of neuronal death with particular attention on dopaminergic death. In conclusion with our work, we confirmed that diet is the best medicine in several disorders, including neurodegenerative disease and in particular we demonstrated for the first time that Açai berry supplementation at the dose of 500 mg/kg was useful to counteract the neuroinflammatory and oxidative events characteristic of the PD, limiting neuronal death and improving physiological antioxidant defense.